Switch theme
Sign up to access all valuation multiples
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
2015
1.7K+
LTM Revenue $1.4B
LTM EBITDA $379M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ingevity has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $379M.
In the most recent fiscal year, Ingevity achieved revenue of $1.4B and an EBITDA of -$330M.
Ingevity expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ingevity valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Profit | $484M | XXX | $455M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $379M | XXX | -$330M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | -23% | XXX | XXX | XXX |
| EBIT | $276M | XXX | $260M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | -$99.5M | XXX | -$430M | XXX | XXX | XXX |
| Net Margin | -7% | XXX | -31% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Ingevity's stock price is $42.
Ingevity has current market cap of $1.5B, and EV of $2.9B.
See Ingevity trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $1.5B | XXX | XXX | XXX | XXX | $3.94 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Ingevity has market cap of $1.5B and EV of $2.9B.
Ingevity's trades at 2.1x EV/Revenue multiple, and -8.8x EV/EBITDA.
Equity research analysts estimate Ingevity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ingevity has a P/E ratio of -15.5x.
See valuation multiples for Ingevity and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 7.7x | XXX | -8.8x | XXX | XXX | XXX |
| EV/EBIT | 10.6x | XXX | 11.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -15.5x | XXX | -3.6x | XXX | XXX | XXX |
| EV/FCF | 18.8x | XXX | 57.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIngevity's last 12 month revenue growth is 0%
Ingevity's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.1M for the same period.
Ingevity's rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ingevity's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Ingevity and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | 0% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | -23% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 38% | XXX | XXX | XXX |
| Rule of 40 | 13% | XXX | -23% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ingevity acquired XXX companies to date.
Last acquisition by Ingevity was XXXXXXXX, XXXXX XXXXX XXXXXX . Ingevity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Ingevity founded? | Ingevity was founded in 2015. |
| Where is Ingevity headquartered? | Ingevity is headquartered in United States of America. |
| How many employees does Ingevity have? | As of today, Ingevity has 1.7K+ employees. |
| Who is the CEO of Ingevity? | Ingevity's CEO is Mr. David H. Li. |
| Is Ingevity publicy listed? | Yes, Ingevity is a public company listed on NYS. |
| What is the stock symbol of Ingevity? | Ingevity trades under NGVT ticker. |
| When did Ingevity go public? | Ingevity went public in 2016. |
| Who are competitors of Ingevity? | Similar companies to Ingevity include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Ingevity? | Ingevity's current market cap is $1.5B |
| What is the current revenue of Ingevity? | Ingevity's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Ingevity? | Ingevity revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Ingevity? | Current revenue multiple of Ingevity is 2.1x. |
| Is Ingevity profitable? | Yes, Ingevity is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ingevity? | Ingevity's last 12 months EBITDA is $379M. |
| What is Ingevity's EBITDA margin? | Ingevity's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Ingevity? | Current EBITDA multiple of Ingevity is 7.7x. |
| What is the current FCF of Ingevity? | Ingevity's last 12 months FCF is $155M. |
| What is Ingevity's FCF margin? | Ingevity's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Ingevity? | Current FCF multiple of Ingevity is 18.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
